ReviewFrontiers in immunology2018
Viral-Bacterial Co-infections in the Cystic Fibrosis Respiratory Tract.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 124 citations in OpenAlex.
- Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.Annals of the American Thoracic Society · 2024Trial
- The redefined identity ofJournal of bacteriology · 2026Review
- Systemic and airway T cell dynamics with influenza-specific immune recovery by cystic fibrosis elexacaftor/tezacaftor/ivacaftor therapy.Respiratory research · 2026Article
- Distinct regulatory elements of SLC6A14 expression contribute to modification of cystic fibrosis phenotypes.Human genetics · 2026Article
- Viral Infection Correlates with a Better Clinical Outcome than Pulmonary Exacerbation of Bacterial Origin in Paediatric Patients with Cystic Fibrosis.Pathogens (Basel, Switzerland) · 2025Article
- Potential Resistance Mechanisms Exhibited by Cystic Fibrosis Patients Against SARS-CoV-2.Viruses · 2025Review
- Validation of a Cystic Fibrosis Co-Culture Model for the Identification of Dual Acting Compounds with Antibiotic and Antibiotic Adjuvant Properties.ACS infectious diseases · 2025Article
- Induced Pluripotent (iPSC) and Mesenchymal (MSC) Stem Cells for In Vitro Disease Modeling and Regenerative Medicine.International journal of molecular sciences · 2025Review
- Quercetin and Its Lecithin-Based Formulation: Potential Applications for Allergic Diseases Based on a Narrative Review.Nutrients · 2025Review
- Uncomplicated SARS-CoV-2 Infections with Preserved Lung Function in Pediatric Patients with Cystic Fibrosis: A Three-Year Single-Centre Experience.Journal of clinical medicine · 2025Article
- Distinct Responses of Cystic Fibrosis Epithelial Cells to SARS-CoV-2 and Influenza A Virus.American journal of respiratory cell and molecular biology · 2025Article
- Respiratory microbiota, host immunity, respiratory viral infections and malignant tumors.Frontiers in microbiology · 2025Review
- Genome-wide association study of susceptibility toThe European respiratory journal · 2024Article
- A New Frontier in Cystic Fibrosis Pathophysiology: How and When Clock Genes Can Affect the Inflammatory/Immune Response in a Genetic Disease Model.Current issues in molecular biology · 2024Review
- Article
- Sphingosine Prevents Rhinoviral Infections.International journal of molecular sciences · 2024Article
- Complete Genome Sequences of Four Mycobacteriophages Involved in Directed Evolution against UndisputedMicroorganisms · 2024Article
- Positioning the preventive potential of microbiome treatments for cystic fibrosis in the context of current therapies.Cell reports. Medicine · 2024Review
- Marine bacteriophages disturb the associated microbiota ofFrontiers in microbiology · 2024Article
- Analysis of Phenotypic and Genotypic Susceptibility to Clarithromycin and Amikacin ofMicroorganisms · 2023Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
A majority of the morbidity and mortality associated with the genetic disease Cystic Fibrosis (CF) is due to lung disease resulting from chronic respiratory infections. The CF airways become chronically colonized with bacteria in childhood, and over time commensal lung microbes are displaced by bacterial pathogens, leading to a decrease in microbial diversity that correlates with declining patient health. Infection with the pathogen
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.